Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tislelizumab Plus Chemotherapy and Concurrent Thoracic Radiotherapy as First-line Therapy for Extensive-stage Small-Cell Lung Cancer (ES-SCLC): an Multicenter, Single Arm Prospective Trial

NCT06536868 is registered in ClinicalTrials.gov with Second Hospital of Shanxi Medical University as lead sponsor.

NCT NCT06536868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06536868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tislelizumab Plus Chemotherapy and Concurrent Thoracic Radiotherapy as First-line Therapy for Extensive-stage Small-Cell Lung Cancer (ES-SCLC): an Multicenter, Single Arm Prospective Trial
Lead sponsor
Second Hospital of Shanxi Medical University
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2024
Completion date
December 31, 2026
Enrollment
40 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small-cell lung cancer